Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sensei Biotherapeutics, Inc. (SNSE : NSDQ)

• Company Description    Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company's product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $8.98 Daily Weekly Monthly 20 Day Moving Average: 10,661 shares Shares Outstanding: 1.26 (millions) Market Capitalization: $11.33 (millions) Beta: 0.27 52 Week High: $17.40 52 Week Low: $5.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.73% 17.63% 12 Week 20.05% 9.05% Year To Date -8.39% -14.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1405 RESEARCH BLVD SUITE 125 - ROCKVILLE,MD 20850 USA ph: 240-243-8000 fax: - ir@senseibio.com http://www.senseibio.com

• General Corporate Information    Officers John Celebi - Chief Executive Officer; President and Director William Ringo - Chairman Josiah Craver - Senior Vice President of Finance Bob Holmen - Director James Peyer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81728A207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 1.26 Most Recent Split Date: 6.00 (0.05:1) Beta: 0.27 Market Capitalization: $11.33 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-4.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-18.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.41 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 30.18% vs. Previous Quarter: 27.59% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -72.13 03/31/25 - -66.72 12/31/24 - -59.96 ROA 06/30/25 - -61.35 03/31/25 - -57.10 12/31/24 - -51.90 Current Ratio 06/30/25 - 7.64 03/31/25 - 6.82 12/31/24 - 7.70 Quick Ratio 06/30/25 - 7.64 03/31/25 - 6.82 12/31/24 - 7.70 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 21.66 03/31/25 - 25.38 12/31/24 - 30.52 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.01 03/31/25 - 0.11 12/31/24 - 0.25

Powered by Zacks Investment Research ©